Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma

Amneal Pharmaceuticals Inc. and Shilpa Medicare Limited announced the U.S. launch of Boruzu, a new presentation of ...

APRIL 4, 2025

FDA Approves Calquence With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma

The FDA has granted traditional approval to Calquence with bendamustine and rituximab for adults with previously ...

JANUARY 21, 2025

Jaypirca Approved for Relapsed or Refractory Mantle Cell Lymphoma

The FDA granted accelerated approval to Jaypirca for relapsed or refractory MCL after at least two lines of ...

FEBRUARY 13, 2023

BTK Inhibitor Challenges Standard of Care in Younger Patients With MCL

Already widely considered a standard first-line treatment in older adults with mantle cell lymphoma (MCL), a Bruton ...

JANUARY 11, 2023

Relapsed/Refractory Mantle Cell Lymphoma: Promising Treatments on the Horizon

A rare and incurable form of non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a very heterogeneous disease that ...

DECEMBER 2, 2022

Tecartus Approved as First CAR T-Cell Therapy for Mantle Cell Lymphoma

The FDA approved the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus, Kite) for ...

JULY 29, 2020

FDA Approves BTK Inhibitor Calquence for Mantle Cell Lymphoma

The FDA granted accelerated approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with ...

NOVEMBER 2, 2017